Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis

Part of paid clinical trials in Gainesville, Florida.

Sponsor
University of Florida
Study ID
NCT05110937
Status
Recruiting
Apply to this trial

Conditions

  • Sepsis
  • Trauma Injury

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Accepted

Interventions

  • Blood sampling — OTHER
    Blood sampling

Study Details

Adverse outcomes in surgical sepsis patients are secondary to dysregulated emergency myelopoiesis, and expansion of myeloid-derived suppressor cells. Here we propose to determine the underlying mechanisms behind the increased expansion of these leukocyte populations and the underlying mechanisms that drive inflammation and immune suppression.

Key Dates

Start date
Jan 4, 2022
Status verified
Dec 2025
Primary completion
Jul 31, 2026
Completion
Apr 30, 2027

Study Design

Enrollment
450 participants (estimated)

Arms

  • Arm: Sepsis
    Blood collection: Blood will be collected from patient at day 4, day 7, day 14-21 and at 3 and 6 months.
  • Arm: Healthy Controls
    Blood Collection. The healthy volunteer participants will donate a blood sample. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
  • Arm: Trauma
    Blood collection: Blood will be collected from patient at day 4, day 7, day 14-21 and at 3 and 6 months.

Primary Outcome Measure

The total number of neutrophils and early myeloid derived suppressor cells will be measured and will be used to determine the magnitude of myelopoiesis dysfunction. [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UF Health at Shands hospitalGainesvilleFlorida32610
Jennifer Lanz, MSN
[email protected]
352-273-5497
Ruth Davis, BSN
[email protected]
325-273-5897

Find similar trials in Gainesville, FL

By research site
UF Health at Shands hospital· Gainesville, FL

Related Studies